Citations (97)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (16)
Valdimar B. Kristjánsson, Sigrún H. Lund, Gerður Gröndal, Signý V. Sveinsdóttir, Hjálmar R. Agnarsson, Jón G. Jónasson & Einar S. Björnsson. (2021) Increased risk of inflammatory bowel disease among patients treated with rituximab in Iceland from 2001 to 2018. Scandinavian Journal of Gastroenterology 56:1, pages 46-52.
Read now
Read now
Apostolia Papalexandri, Maria Karypidou, Evangelia Stalika, Konstantina Kotta, Tasoula Touloumenidou, Panagiota Zerva, Angeliki Paleta, Despina Mallouri, Ioannis Batsis, Ioanna Sakellari, Ioannis Kotsianidis, Achilles Anagnostopoulos, Anastasia Hadzidimitriou, Dimitris Margaritis & Kostas Stamatopoulos. (2019) Skewing of the T-cell receptor repertoire in patients receiving rituximab after allogeneic hematopoietic cell transplantation: what lies beneath?. Leukemia & Lymphoma 60:7, pages 1685-1692.
Read now
Read now
Omid Rezahosseini, Sara Hanaei, Mehdi Hamadani, Mahsa Keshavarz-Fathi & Nima Rezaei. (2018) The promising role of monoclonal antibodies for immunotherapy of the HIV-associated cancer, non-Hodgkin lymphoma. International Reviews of Immunology 37:3, pages 165-173.
Read now
Read now
J Vikse, A Rygh, K Kaisen & R Omdal. (2017) Life-threatening rituximab-induced pyoderma gangrenosum successfully treated with intravenous immunoglobulin. Scandinavian Journal of Rheumatology 46:5, pages 413-414.
Read now
Read now
Poornima Varma, Julianne Falconer, Ahmad Aga, H. Miles Prince & Stephen Pianko. (2017) Rituximab-induced Crohn’s disease. Scandinavian Journal of Gastroenterology 52:5, pages 606-608.
Read now
Read now
Yasuyuki Arai, Kouhei Yamashita, Kiyomi Mizugishi, Momoko Nishikori, Masakatsu Hishizawa, Tadakazu Kondo, Toshiyuki Kitano, Hiroshi Kawabata, Norimitsu Kadowaki & Akifumi Takaori-Kondo. (2015) Risk factors for late-onset neutropenia after rituximab treatment of B-cell lymphoma. Hematology 20:4, pages 196-202.
Read now
Read now
Edward Chew, Karin Thursky & John F. Seymour. (2014) Very late onset hepatitis-B virus reactivation following rituximab despite lamivudine prophylaxis: the need for continued vigilance. Leukemia & Lymphoma 55:4, pages 938-939.
Read now
Read now
Evangelia Stalika, George Kanellis, Apostolia Papalexandri, Michalis Iskas, Efimia Vrakidou, Maria Demonakou, Achilles Anagnostopoulos, Kostas Stamatopoulos & Theodora Papadaki. (2014) Cytotoxic T cell-mediated gastritis after rituximab treatment for gastric malt lymphoma. Leukemia & Lymphoma 55:3, pages 702-705.
Read now
Read now
Shawn Shetty & A. R. Ahmed. (2013) Preliminary analysis of mortality associated with rituximab use in autoimmune diseases. Autoimmunity 46:8, pages 487-496.
Read now
Read now
Annika Deiß, Isabel Brecht, Axel Haarmann & Mathias Buttmann. (2013) Treating multiple sclerosis with monoclonal antibodies: a 2013 update. Expert Review of Neurotherapeutics 13:3, pages 313-335.
Read now
Read now
Tadeusz Robak, Pawel Robak & Piotr Smolewski. (2012) The evaluation and optimal use of rituximab in lymphoid malignancies. Blood and Lymphatic Cancer: Targets and Therapy 2, pages 1-16.
Read now
Read now
Jan Novak, Heidi Mocikova, Petr Pavlicek, Lubica Gaherova & Tomas Kozak. (2012) Rituximab-induced coagulopathy. Leukemia & Lymphoma 53:11, pages 2299-2301.
Read now
Read now
Samo Rozman, Monika Sonc & Barbara Jezersek Novakovic. (2012) Late-onset neutropenia following primary treatment of diff use large B-cell lymphoma with rituximab-containing therapy. Leukemia & Lymphoma 53:10, pages 1945-1948.
Read now
Read now
Daniel Tesfa & Jan Palmblad. (2011) Late-onset neutropenia following rituximab therapy: incidence, clinical features and possible mechanisms. Expert Review of Hematology 4:6, pages 619-625.
Read now
Read now
José Francisco Tomás, Carlos Montalbán, Alberto Fernández De Sevilla, JoaquÍn MartÍnez-lópez, Nicolás DÍaz, Miguel Canales, Rafael MartÍnez, Pedro Sánchez-Godoy, MarÍa Dolores Caballero, Javier Peñalver, Elena Prieto, Antonio Salar, Carmen Burgaleta, José Antonio Queizán, Roberto Bajo, Raquel De oña & Javier De La Serna. (2011) Frontline treatment of follicular lymphoma with fludarabine, cyclophosphamide, and rituximab followed by rituximab maintenance: toxicities overcome its high antilymphoma effect. Results from a Spanish Cooperative Trial (LNHF-03). Leukemia & Lymphoma 52:3, pages 409-416.
Read now
Read now
Sylvain Pilorge, Sophie Park, François Dreyfus, Didier Bouscary & Jerome Tamburini. (2010) Rituximab-induced life-threatening coagulopathy occurring in a patient with Waldenström macroglobulinemia treated with fludarabine, cyclophosphamide, and rituximab combination. Leukemia & Lymphoma 51:12, pages 2288-2290.
Read now
Read now
Articles from other publishers (81)
Natalia Gonzalez Caldito, Edith L Graham & Elena Grebenciucova. (2023) Rituximab and pregnancy: Late-onset neutropenia in a 2-month infant whose mother received rituximab 2 weeks prior to childbirth. Multiple Sclerosis Journal.
Crossref
Crossref
Min Xue, Zhenzhen Gao, Miaolong Yan & Yi Bao. (2023) Profiling risk factors for separation of infection complications in patients with gastrointestinal and nodal diffuse large B-cell lymphoma. BMC Infectious Diseases 23:1.
Crossref
Crossref
Zicheng Yu, Haibin Zhu, Hongjun Chen, Lifei Zhu & Xiaolan Liao. (2023) Gastrointestinal perforation associated with novel antineoplastic agents: A real-world study based on the FDA Adverse Event Reporting System. Journal of Pharmacy & Pharmaceutical Sciences 26.
Crossref
Crossref
Mai Alalawi, Abrar Saeed Bakr, Rowaida Reda, Karim Thomas Sadak & Mohamad Nagy. (2022) Late-onset toxicities of monoclonal antibodies in cancer patients. Immunotherapy 14:13, pages 1067-1083.
Crossref
Crossref
Yuliya Lytvyn, Asfandyar Mufti, Khalad Maliyar, Muskaan Sachdeva & Jensen Yeung. (2022) Onset of Pyoderma Gangrenosum in Patients on Biologic Therapies: A Systematic Review. Advances in Skin & Wound Care 35:8, pages 454-460.
Crossref
Crossref
Jing Yang, Limin Chai, Junting Jia, Liping Su & Zhiying Hao. (2022) Meta-Analysis of Risk Factors and Incidence of Interstitial Pneumonia With CHOP-Like Regimens for Non-Hodgkin Lymphoma. Frontiers in Oncology 12.
Crossref
Crossref
T. Angel Miraclin, Ajith Sivadasan, Rutvi Gautam Dave, Rohit NB, Prabhakar AT, Nitty Skariah Mathews, John A.J. Prakash, Vivek Mathew, Sanjith Aaron & Mathew Alexander. (2022) Rituximab therapy for neuro - inflammatory disorders – Real world experience from South India. Journal of Neuroimmunology 367, pages 577862.
Crossref
Crossref
Wen Wei, Yajie Zhu, Jianning Tang, Chuan Xu, Jiman Li, Shuya He, Zhihui Zhang, Ping Wu, Lei Luo, Qin Guo, Fang Li, Yuanrong Ren, Sisi Yu, Renqin Li & Li Li. (2021) Not all bad: Drug-induced interstitial pneumonia in DLBCL patients is potentially fatal but could be linked to better survival. Leukemia Research 111, pages 106688.
Crossref
Crossref
Fanxin Kong, Jianjun Wang, Haotao Zheng, Haobin Cai, Jun Hua & Liling Li. (2021) Monoclonal Antibody Therapy in Neuromyelitis Optica Spectrum Disorders: a Meta-analysis of Randomized Control Trials. Frontiers in Pharmacology 12.
Crossref
Crossref
Yoshikazu Tsuzuki, Rie Shiomi, Keigo Ashitani, Kazuya Miyaguchi, Atsushi Osaki, Hideki Ohgo, Rei Kim, Atsushi Sasaki, Taketo Yamada, Yoshitaka Miyakawa, Hidetomo Nakamoto & Hiroyuki Imaeda. (2021) Rituximab-induced Ileocolitis in a Patient with Gastric MALToma: A Case Report and Literature Review. Internal Medicine 60:5, pages 731-738.
Crossref
Crossref
Karan Seegobin, Muhamad A. Moustafa, Nicole Gannon, Katelyn Keller, Jacquelyn Hastings, Vivek Gupta, Han W. Tun & Liuyan Jiang. (2021) Successful treatment of IgG4‐related hypertrophic pachymeningitis with induction rituximab and dexamethasone followed by maintenance rituximab. Clinical Case Reports 9:3, pages 1610-1614.
Crossref
Crossref
Astrid C. van Stigt, Willem A. Dik, Lieke S. J. Kamphuis, Bas M. Smits, Joris M. van Montfrans, P. Martin van Hagen, Virgil A. S. H. Dalm & Hanna IJspeert. (2020) What Works When Treating Granulomatous Disease in Genetically Undefined CVID? A Systematic Review. Frontiers in Immunology 11.
Crossref
Crossref
Thomas Kiefer, Dorothea Krahl, Thomas Kohlmann, Axel Nogai, Herrad Baurmann, Frank Schüler, William Krüger, Maike Wit, Daniel Pink, Marion Dietz, Heinz Völler, Hermann Buhlert & Georg Daeschlein. (2020) Does rehabilitation pose a risk to patients suffering from haemato‐oncological diseases? Results of a monocentric, retrospective analysis in Germany. European Journal of Cancer Care 29:2.
Crossref
Crossref
Bo Kyung Kim, Hyoung Jin Kang, Kyung Taek Hong, Hong Yul An, Jung Yoon Choi, Jee Soo Lee, Sung Sup Park & Hee Young Shin. (2019) Successful preemptive therapy with single‐dose rituximab for Epstein‐Barr virus infection to prevent post‐transplant lymphoproliferative disease after pediatric hematopoietic stem cell transplantation. Transplant Infectious Disease 21:6.
Crossref
Crossref
Jens Vikse, Kristin Jonsdottir, Jan Terje Kvaløy, Klaus Wildhagen & Roald Omdal. (2019) Tolerability and safety of long-term rituximab treatment in systemic inflammatory and autoimmune diseases. Rheumatology International 39:6, pages 1083-1090.
Crossref
Crossref
Jonas Graf, Orhan Aktas, Konrad Rejdak & Hans-Peter Hartung. (2019) Monoclonal Antibodies for Multiple Sclerosis: An Update. BioDrugs 33:1, pages 61-78.
Crossref
Crossref
Brianne J Sullivan, Grace J Kim & Gabriel Sara. (2018) Treatment dilemma for survivors of rituximab-induced bowel perforation in the setting of post-transplant lymphoproliferative disorder. BMJ Case Reports 11:1, pages e226666.
Crossref
Crossref
Sandra LockmerBjørn ØstenstadHans HagbergHarald HolteAnn-Sofie JohanssonBjörn Engelbrekt WahlinKarin Fahl WaderChloé Beate SteenPeter MeyerMartin MaisenhølderKarin Ekström SmedbyPeter BrownEva Kimby. (2018) Chemotherapy-Free Initial Treatment of Advanced Indolent Lymphoma Has Durable Effect With Low Toxicity: Results From Two Nordic Lymphoma Group Trials With More Than 10 Years of Follow-Up. Journal of Clinical Oncology 36:33, pages 3315-3323.
Crossref
Crossref
Marion Alcantara, Melania Tesio, Carl H. June & Roch Houot. (2018) CAR T-cells for T-cell malignancies: challenges in distinguishing between therapeutic, normal, and neoplastic T-cells. Leukemia 32:11, pages 2307-2315.
Crossref
Crossref
Catherine Maloney, Nicholas Blickenstaff, Aman Kugasia, Laura Beth Buford & Mark D. Hoffman. (2018) Vulvovaginal pyoderma gangrenosum in association with rituximab. JAAD Case Reports 4:9, pages 907-909.
Crossref
Crossref
Sareh Shahmohammadi, Mohammad Ali Sahraian, Abootorab Shahmohammadi, Rozita Doosti, Ali Zare-Mirzaie & Abdorreza Naser Moghadasi. (2018) A presentation of ulcerative colitis after rituximab therapy in a patient with multiple sclerosis and literature review. Multiple Sclerosis and Related Disorders 22, pages 22-26.
Crossref
Crossref
Eero Rissanen, Kari Remes & Laura Airas. (2018) Severe neutropenia after rituximab-treatment of multiple sclerosis. Multiple Sclerosis and Related Disorders 20, pages 3-5.
Crossref
Crossref
E. Ghrenassia, E. Mariotte & E. Azoulay. 2018. Annual Update in Intensive Care and Emergency Medicine 2018. Annual Update in Intensive Care and Emergency Medicine 2018
579
596
.
Nannan Zhang, Guo Zhang, Ning Liu, Wanting Lin, Sen Ji, Mingwu Zheng, Kai Chen, Xiao Liang, Guobo Li, Yu Ma, Jun Zhu, Ting Niu, Lin-Li Li, Jiong Li, Yu-Quan Wei & Sheng-Yong Yang. (2017) A novel orally available Syk/Src/Jak2 inhibitor, SKLB-850, showed potent anti-tumor activities in B cell lymphoma (BCL) models. Oncotarget 8:67, pages 111495-111507.
Crossref
Crossref
Farzin Forooghian & Ian M. MacDonald. (2017) Rituximab for the Treatment of Autoimmune Retinopathy. American Journal of Ophthalmology 180, pages xv-xvi.
Crossref
Crossref
I García-Cadenas, I Rivera, R Martino, A Esquirol, P Barba, S Novelli, G Orti, J Briones, S Brunet, D Valcarcel & J Sierra. (2016) Patterns of infection and infection-related mortality in patients with steroid-refractory acute graft versus host disease. Bone Marrow Transplantation 52:1, pages 107-113.
Crossref
Crossref
Marina Vivarelli, Manuela Colucci, Alice Bonanni, Martina Verzani, Jessica Serafinelli, Francesco Emma & Gianmarco Ghiggeri. (2016) Ofatumumab in two pediatric nephrotic syndrome patients allergic to rituximab. Pediatric Nephrology 32:1, pages 181-184.
Crossref
Crossref
Emilio Besada & Johannes C. Nossent. (2016) CD4 cell count and CD4/CD8 ratio increase during rituximab maintenance in Granulomatosis with polyangiitis patients. PeerJ 4, pages e2487.
Crossref
Crossref
David Aguiar-Bujanda, María Jesús Blanco-Sánchez, María Hernández-Sosa, Saray Galván-Ruíz, Samuel Hernández-Sarmiento, Salvador Saura-Grau & Uriel Bohn-Sarmiento. (2015) Late-Onset Neutropenia After Rituximab-Containing Therapy for Non-Hodgkin Lymphoma. Clinical Lymphoma Myeloma and Leukemia 15:12, pages 761-765.
Crossref
Crossref
Antoine Froissart, Agn?s Veyradier, Miguel Hi?Ygal Benhamou & Paul Coppo. (2015) Rituximab in autoimmune thrombotic thrombocytopenic purpura: A success story. European Journal of Internal Medicine 26:9, pages 659-665.
Crossref
Crossref
Adriano M. Pellicelli, Cecilia D’Ambrosio, Maria L. Dessanti, Roberto Villani, Lucia Fondacaro, Lucia Miglioresi, Lucia R. Grillo & Arnaldo Andreoli. (2015) Cholestatic hepatitis C after chemotherapy containing rituximab in diffuse large B cell lymphoma. Annals of Hepatology 14:5, pages 756-761.
Crossref
Crossref
Øystein Fluge, Kristin Risa, Sigrid Lunde, Kine Alme, Ingrid Gurvin Rekeland, Dipak Sapkota, Einar Kleboe Kristoffersen, Kari Sørland, Ove Bruland, Olav Dahl & Olav Mella. (2015) B-Lymphocyte Depletion in Myalgic Encephalopathy/ Chronic Fatigue Syndrome. An Open-Label Phase II Study with Rituximab Maintenance Treatment. PLOS ONE 10:7, pages e0129898.
Crossref
Crossref
Xuqin Jiang, Xiaodong Mei, Di Feng & Xiaojing Wang. (2015) Prophylaxis and Treatment of Pneumocystis jiroveci Pneumonia in Lymphoma Patients Subjected to Rituximab-Contained Therapy: A Systemic Review and Meta-Analysis. PLOS ONE 10:4, pages e0122171.
Crossref
Crossref
Caroline Le Jeune & Xavier Thomas. (2015) Antibody-based therapies in B-cell lineage acute lymphoblastic leukaemia. European Journal of Haematology 94:2, pages 99-108.
Crossref
Crossref
Jennifer Worch, Olga Makarova & Birgit Burkhardt. (2015) Immunreconstitution and Infectious Complications After Rituximab Treatment in Children and Adolescents: What Do We Know and What Can We Learn from Adults?. Cancers 7:1, pages 305-328.
Crossref
Crossref
Kathryn M Pietrosimone. (2015) Contributions of neutrophils to the adaptive immune response in autoimmune disease. World Journal of Translational Medicine 4:3, pages 60.
Crossref
Crossref
Olga Reitblat. (2015) Rituximab-Related Late-Onset Neutropenia in Patients with Rheumatic Diseases: Successful Re-Challenge of the Treatment. American Journal of Case Reports 16, pages 211-214.
Crossref
Crossref
Mehdi Khellaf, Anaïs Charles-NelsonOlivier FainLouis TerriouJean-François ViallardStéphane ChezeJulie GraveleauBorhane SlamaSylvain AudiaMikael EbboGuillaume Le GuennoManuel CliquennoisGilles SallesCaroline BonmatiFrance TeilletLionel GalicierArnaud HotOlivier LambotteFrançois LefrèreSalimatou SackoDieudonné Kilendo KenguePhilippe Bierling, Françoise Roudot-Thoraval, Marc Michel & Bertrand Godeau. (2014) Safety and efficacy of rituximab in adult immune thrombocytopenia: results from a prospective registry including 248 patients. Blood 124:22, pages 3228-3236.
Crossref
Crossref
Emilio Besada, Wenche Koldingsnes & Johannes C. Nossent. (2014) Serum immunoglobulin levels and risk factors for hypogammaglobulinaemia during long-term maintenance therapy with rituximab in patients with granulomatosis with polyangiitis. Rheumatology 53:10, pages 1818-1824.
Crossref
Crossref
Daniel Shepshelovich, Talia Diker-Cohen & Meir Lahav. (2014) Searching for the leak. American Journal of Hematology 89:9, pages 928-930.
Crossref
Crossref
Aline Autrel-Moignet & Thierry Lamy. (2014) Autoimmune neutropenia. La Presse Médicale 43:4, pages e105-e118.
Crossref
Crossref
Qifa Liu, Li Xuan, Hui Liu, Fen Huang, Hongsheng Zhou, Zhiping Fan, Ke Zhao, Meiqing Wu, Lanping Xu, Xiao Zhai, Fuhua Zhang, Can Liu, Jing Sun & Xiaojun Huang. (2013) Molecular monitoring and stepwise preemptive therapy for Epstein-Barr virus viremia after allogeneic stem cell transplantation. American Journal of Hematology 88:7, pages 550-555.
Crossref
Crossref
Yongkang Wu, Yongqian Jia, Juan Xu, Xiao Shuai & Yu Wu. (2013) Fatal interstitial lung disease induced by rituximab-containing chemotherapy, treatment with TNF-α antagonist and cytokine profiling: a case-report and review of the literature. Journal of Clinical Pharmacy and Therapeutics 38:3, pages 249-253.
Crossref
Crossref
Lorenzo Cavagna, Sara Monti, Vittorio Grosso, Nicola Boffini, Eva Scorletti, Gloria Crepaldi & Roberto Caporali. (2013) The Multifaceted Aspects of Interstitial Lung Disease in Rheumatoid Arthritis. BioMed Research International 2013, pages 1-13.
Crossref
Crossref
Karen D. Price & Gautham K. Rao. 2013. Nonclinical Development of Novel Biologics, Biosimilars, Vaccines and Specialty Biologics. Nonclinical Development of Novel Biologics, Biosimilars, Vaccines and Specialty Biologics
303
342
.
Phil A. Hart & Suresh T. Chari. 2013. Autoimmune (IgG4-related) Pancreatitis and Cholangitis. Autoimmune (IgG4-related) Pancreatitis and Cholangitis
111
120
.
V. Selvarajah, A. J. Montano‐Loza & A. J. Czaja. (2012) Systematic review: managing suboptimal treatment responses in autoimmune hepatitis with conventional and nonstandard drugs. Alimentary Pharmacology & Therapeutics 36:8, pages 691-707.
Crossref
Crossref
Thijs J. Giezen, Aukje K. Mantel‐Teeuwisse, Maarten J. ten Berg, Sabine M. J. M. Straus, Hubert G. M. Leufkens, Wouter W. van Solinge & Toine C. G. Egberts. (2012) Rituximab‐induced thrombocytopenia: a cohort study. European Journal of Haematology 89:3, pages 256-266.
Crossref
Crossref
Linda Lee, Michael Crump, Sara Khor, Jeffrey S. Hoch, Jin Luo, Karen Bremner, Murray Krahn & David C. Hodgson. (2012) Impact of rituximab on treatment outcomes of patients with diffuse large b‐cell lymphoma: a population‐based analysis. British Journal of Haematology 158:4, pages 481-488.
Crossref
Crossref
Peter J Bugelski & Pauline L Martin. (2012) Concordance of preclinical and clinical pharmacology and toxicology of therapeutic monoclonal antibodies and fusion proteins: cell surface targets. British Journal of Pharmacology 166:3, pages 823-846.
Crossref
Crossref
P Barba, I Garcia-Cadenas, J Nomdedéu, R Martino, L Gallur & D Valcárcel. (2011) Rituximab treatment may disturb the normal pattern of lymphopoiesis after cord blood SCT. Bone Marrow Transplantation 47:3, pages 458-460.
Crossref
Crossref
YUJIN KOBAYASHI, YOSHIHIRO HATTA, ATSUKO HOJO, YOSHIMASA KURA, YOSHIHITO UCHINO, HIROMICHI TAKAHASHI, SATOMI KISO, YUKIO HIRABAYASHI, MAI YAGI, HITOMI KODAIRA, DAISUKE KURITA, TOSHITAKE TANAKA, KATSUHIRO MIURA, NORIYOSHI IRIYAMA, SUMIKO KOBAYASHI, UMIHIKO SAWADA, MASAHIKO SUGITANI & JIN TAKEUCHI. (2012) Long-term follow-up of localized, primary gastric diffuse large B-cell lymphoma treated with rituximab and CHOP. Experimental and Therapeutic Medicine 3:2, pages 304-308.
Crossref
Crossref
Emilio Besada. (2012) Rituximab og nøytropeni. Tidsskrift for Den norske legeforening 132:20, pages 2259-2259.
Crossref
Crossref
Nishkantha Arulkumaran, Rashid Suleman, Maurizio Cecconi, Patrick Kiely & Felix Chua. (2012) Rituximab Associated Pneumonitis in Antineutrophil Cytoplasmic Antibody–Associated Vasculitis. JCR: Journal of Clinical Rheumatology 18:1, pages 39-41.
Crossref
Crossref
Ofir Wolach, Ofer Shpilberg & Meir Lahav. (2012) Neutropenia after rituximab treatment. Current Opinion in Hematology 19:1, pages 32-38.
Crossref
Crossref
Harumi Kato, Kazuhito Yamamoto, Hirofumi Taji, Yasuhiro Oki, Dai Chihara, Masao Seto, Yoshitoyo Kagami & Yasuo Morishima. (2011) Interstitial Pneumonia After Autologous Hematopoietic Stem Cell Transplantation in B-Cell Non-Hodgkin Lymphoma. Clinical Lymphoma Myeloma and Leukemia 11:6, pages 483-489.
Crossref
Crossref
Moon Jin Kim, Gyeong-Won Lee, Jong Woo Seo, Hyun-Jung Kim, Sung-Nam Lim & Cheolwon Suh. (2010) Fatal interstitial pneumonitis in a patient with relapsed diffuse large B cell lymphoma following yttrium-90 ibritumomab tiuxetan. Investigational New Drugs 29:5, pages 1098-1101.
Crossref
Crossref
Yuji Hirai, Yusuke Ainoda, Takayo Shoji, Takahiro Fujita, Kentaro Yoshinaga, Masayuki Shiseki, Naoki Mori, Masanao Teramura, Kyoichi Totsuka & Toshiko Motoji. (2011) Disseminated Cryptococcosis in a Non-Hodgkin’s Lymphoma Patient with Late-Onset Neutropenia Following Rituximab-CHOP Chemotherapy: A Case Report and Literature Review. Mycopathologia 172:3, pages 227-232.
Crossref
Crossref
Kamal S. Saini, Hatem A. AzimJr.Jr., Emilia Cocorocchio, Anna Vanazzi, Monika Lamba Saini, Paola Rafaniello Raviele, Giancarlo Pruneri & Fedro A. Peccatori. (2011) Rituximab in Hodgkin lymphoma: Is the target always a hit?. Cancer Treatment Reviews 37:5, pages 385-390.
Crossref
Crossref
Daniel L. Keene, Carole Legare, Elaine Taylor, Jim Gallivan, Gloria Mah Cawthorn & Duc Vu. (2014) Monoclonal Antibodies and Progressive Multifocal Leukoencephalopathy. Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques 38:4, pages 565-571.
Crossref
Crossref
A. G. Singh, I. S. Hamarneh, M. W. Karwal & S. R. Lentz. (2011) Durable responses to rituximab in acquired factor VIII deficiency. Thrombosis and Haemostasis 106:1, pages 172-174.
Crossref
Crossref
Daan Dierickx, André Delannoy, Khalid Saja, Gregor Verhoef & Drew Provan. (2011) Anti-CD20 monoclonal antibodies and their use in adult autoimmune hematological disorders. American Journal of Hematology 86:3, pages 278-291.
Crossref
Crossref
Piers Blombery, H. Miles Prince, Michele Levinson, Stephen Pianko, Ellen Maxwell & Prithi Bhathal. (2011) Rituximab-Induced Immunodysregulatory Ileocolitis in a Patient With Follicular Lymphoma. Journal of Clinical Oncology 29:5, pages e110-e112.
Crossref
Crossref
Massimo Marignani, Manuela Mangone, M. Christina Cox, Stefano Angeletti, Barbara Veggia, Antonella Ferrari, Michela di Fonzo, Paola Begini, Elia Gigante, Giacinto Laverde, Antonietta Aloe-Spiriti, Bruno Monarca & Gianfranco Delle Fave. (2011) HCV-positive status and hepatitis flares in patients with B-cell non-Hodgkin's lymphoma treated with rituximab-containing regimens. Digestive and Liver Disease 43:2, pages 139-142.
Crossref
Crossref
Emilio Martín Mola, Blanca Hernández, Miriam García-Arias, José María Álvaro-Gracia, Alejandro Balsa, Juan Gómez-Reino, José L. Marenco de la Fuente, Víctor Martínez-Taboada, José Andrés Román Ivorra & Raimon Sanmartí. (2011) Consensus on the use of Rituximab in Rheumatoid Arthritis. A document with evidence based recommendations. Reumatología Clínica (English Edition) 7:1, pages 30-44.
Crossref
Crossref
D. Spoerl & Andreas J. Bircher. 2011. A worldwide yearly survey of new data in adverse drug reactions. A worldwide yearly survey of new data in adverse drug reactions
769
814
.
László Maródi & Jean-Laurent Casanova. (2010) Primary immunodeficiencies may reveal potential infectious diseases associated with immune-targeting mAb treatments. Journal of Allergy and Clinical Immunology 126:5, pages 910-917.
Crossref
Crossref
Albert J. Czaja. (2010) Emerging Opportunities for Site-Specific Molecular and Cellular Interventions in Autoimmune Hepatitis. Digestive Diseases and Sciences 55:10, pages 2712-2726.
Crossref
Crossref
Ofir Wolach, Osnat Bairey & Meir Lahav. (2010) Late-Onset Neutropenia After Rituximab Treatment. Medicine 89:5, pages 308-318.
Crossref
Crossref
Eugene P. Rhee, Karen A. Laliberte & John L. Niles. (2010) Rituximab as Maintenance Therapy for Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis. Clinical Journal of the American Society of Nephrology 5:8, pages 1394-1400.
Crossref
Crossref
Anna Maria Lombardi, Giulia Berti de Marinis, Raffaella Scandellari, Francesca Magalini, Paolo Sansoni, Pier Ferruccio Ballerini, Silvia Vettore, Nicole Candeo, Piero Marson, Giustina De Silvestro & Fabrizio Fabris. (2010) Clinical biological remission induced by rituximab in acute refractory chronic relapsing TTP. Thrombosis Research 126:2, pages e154-e156.
Crossref
Crossref
Simone Cesaro, Anna Pegoraro, Gloria Tridello, Elisabetta Calore, Marta Pillon, Stefania Varotto, Davide Abate, Luisa Barzon, Carlo Mengoli, Modesto Carli & Chiara Messina. (2010) A Prospective Study on Modulation of Immunosuppression for Epstein-Barr Virus Reactivation in Pediatric Patients Who Underwent Unrelated Hematopoietic Stem-Cell Transplantation. Transplantation 89:12, pages 1533-1540.
Crossref
Crossref
László Maródi & Jean-Laurent Casanova. (2010) Can primary immunodeficiencies help to provide insights into infectious risks of therapeutic antibodies?. Nature Reviews Immunology 10:5, pages 299-300.
Crossref
Crossref
Agustin Avilés, Natividad Neri, Judith Huerta-Guzmán & María de Jesús Nambo. (2010) ESHAP Versus Rituximab-ESHAP in Frail Patients With Refractory Diffuse Large B-Cell Lymphoma. Clinical Lymphoma Myeloma and Leukemia 10:2, pages 125-128.
Crossref
Crossref
Martin Bitzan, Mark Anselmo & Lucy Carpineta. (2010) Reply: Rituximab-induced pneumonitis: Steroid therapy or not?. Pediatric Pulmonology 45:4, pages 414-416.
Crossref
Crossref
Huguette Lioté, Jacques Cadranel & Frédéric Lioté. (2010) Rituximab-induced pneumonitis: Steroid therapy or not?. Pediatric Pulmonology 45:4, pages 412-413.
Crossref
Crossref
. (2009) Current awareness: Pharmacoepidemiology and drug safety. Pharmacoepidemiology and Drug Safety 19:1.
Crossref
Crossref
Carolyn M. Bennett & Michael Tarantino. (2009) Chronic Immune Thrombocytopenia in Children: Epidemiology and Clinical Presentation. Hematology/Oncology Clinics of North America 23:6, pages 1223-1238.
Crossref
Crossref
Deborah A. Thomas, Susan O'Brien & Hagop M. Kantarjian. (2009) Monoclonal Antibody Therapy with Rituximab for Acute Lymphoblastic Leukemia. Hematology/Oncology Clinics of North America 23:5, pages 949-971.
Crossref
Crossref
Lucy R. Wedderburn & Lisa G. Rider. (2009) Juvenile dermatomyositis: new developments in pathogenesis, assessment and treatment. Best Practice & Research Clinical Rheumatology 23:5, pages 665-678.
Crossref
Crossref
Liat Vidal, Anat Gafter-Gvili, Leonard Leibovici, Martin Dreyling, Michele Ghielmini & Ofer Shpilberg. (2009) Response: Re: Rituximab Maintenance for the Treatment of Patients With Follicular Lymphoma: Systematic Review and Meta-analysis of Randomized trials. JNCI: Journal of the National Cancer Institute 101:18, pages 1289-1290.
Crossref
Crossref